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The last few years have witnessed growing interest in
regenerative therapy for the failing heart by cell transplan-
tation. Although initial studies with skeletal myoblasts are
more than 10 years old, the potential of bone marrow-de-
rived cells has led to a flurry of experimental studies ge-
nerating generally positive but occasionally contradictory
results. This has given rise on not a few occasions to con-
flicting viewpoints regarding the ethics of initiating clinical
trials. We feel it is appropriate to offer a critical view of the
use of stem cells for heart failure. Perhaps the thorniest
question to answer at this time is whether clinical trials
are justified or not in the light of current knowledge, or
whether we should acquire deeper knowledge of the pos-
sible efficacy and safety of this type of treatment, and of
the mechanisms that account for its efficacy, before we
so much as initiate studies in humans. We feel there is
now sufficient evidence to justify the performance of clini-
cal trials despite the undoubtedly numerous questions
that remain to be answered with experimental studies in
animals. 
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INTRODUCTION
The strategic use of stem cell therapy to regenerate
damaged or destroyed tissue seems one of the most
promising developments in the treatment of a substan-
tial number of patients affected by illnesses for which
there is currently little or no hope of cure. The poten-
tial use of cell therapy in heart failure is clearly attrac-
tive due to the high incidence and prevalence of this
disease and the absence of a cure other than heart
transplantation.1 Over the last 10 years, cells derived
from different sources have been grafted into dam-
aged regions of the heart and shown they can produce
functional benefits. Obviously, the greater the expec-
tations a specific treatment raises, the more prudent
we should be in its application and in evaluating re-
sults; we must do our utmost to uphold scientific crite-
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Perspectivas futuras de tratamiento 
en la insuficiencia cardíaca: del trasplante 
de células a la regeneración cardíaca
En los últimos años hemos asistido a un interés creciente
por el tratamiento de la insuficiencia cardíaca mediante el
trasplante de células madre. Mientras que los estudios con
células madre de músculo (mioblastos) se iniciaron hace
más de 10 años, la posibilidad de que las células madre de
la médula ósea tengan un enorme potencial de diferencia-
ción y proliferación ha estimulado la investigación con otros
tipos de células madre. Estos estudios experimentales han
demostrado, en no pocas ocasiones, resultados contradic-
torios, lo que ha llevado a posturas enfrentadas en cuanto a
la ética de iniciar estudios clínicos. Creemos que es ade-
cuado tratar de ofrecer una visión crítica respecto a la utili-
zación de las células madre en la insuficiencia cardíaca.
Quizá la pregunta más difícil de contestar en este momento
es si la realización de ensayos clínicos está justificada o no
a la luz de los conocimientos actuales, o si por el contrario
debemos adquirir un conocimiento mucho más preciso de
la posible eficacia de este tipo de tratamiento y de los me-
canismos que justifican esta eficacia, antes de siquiera ini-
ciar los estudios en humanos. En nuestra opinión, hay sufi-
cientes evidencias que justifican el desarrollo de ensayos
clínicos a pesar de que, sin duda, existen muchos interro-
gantes que debemos resolver mediante estudios experi-
mentales en animales.
Palabras clave: Células madre. Mioblastos. Regenera-
ción cardíaca. Versatilidad.
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ria and thus avoid adverse results that might compro-
mise the future of the new treatment. A recent example
can be seen in the use of gene therapy.2,3
Whatever the case may be, we believe experimental
data and results from the first studies in patients justify
the development of well-designed, rigorously con-
trolled clinical trials in the field of cell therapy for
heart failure. We recognize that opinion is divided
over this issue, from the most optimistic perspectives
to significantly more restrictive views.4 Without doubt,
there are many unknown factors and limitations that
should be researched and resolved prior to cell therapy
becoming part of the arsenal of therapies in heart fail-
ure, but we do not think it justified to demand answers
to all our questions prior to initiating clinical trials.
In the following pages we try to identify some of the
obstacles and the most relevant questions about the ap-
plication of cell therapy in cardiology. These include
the issue of cell types, mechanisms, delivery, possible
secondary effects and indications. In spite of nume-
rous existing studies, most of these questions have yet
to be answered clearly. One of the benefits of the de-
velopment of regenerative medicine is the stimulus it
provides to new diagnostic techniques to evaluate
function, viability, perfusion, etc. For lack of space,
we will not enter into these aspects here, nor will we
discuss more specific issues such as optimal cell deli-
very procedures or indications for cell therapy, as we
believe it somewhat premature to establish indications
for a treatment still under investigation. There are ex-
cellent recent reviews which deal with some of these
issues.5
CARDIAC REGENERATION WITH STEM
CELLS: WHICH TYPE OF CELL IS IDEAL?
Although the alternatives theoretically include the
use of cardiomyocytes, embryonic stem cells, cardiac
stem cells, skeletal myoblasts, or bone marrow-de-
rived stem cells, we will focus principally on those
cell types currently available for clinical use: bone
marrow-derived stem cells and skeletal myoblasts.
Skeletal Myoblasts
There are numerous reasons why satellite cells or
myoblasts were the first type of stem cell used in
myocardial regeneration: their capacity to proliferate
in vitro; their program of development limited to mus-
cular tissue and, thus, with minimal risk of developing
tumors; the possibility of obtaining autologous cells;
and their great resistance to ischemia. Numerous ex-
perimental studies use skeletal myoblasts in models of
acute and chronic infarction in rodents and larger ani-
mals such as pigs or sheep.6 These studies have led us
to a series of conclusions that constitute the justifica-
tion for the clinical trials carried out to date and that
we try to summarize below. Skeletal myoblasts im-
planted in animals with myocardial infarction are ca-
pable of engraftment both in and around the infarcted
area and differentiate into multinuclear myotubes.
Some studies detected implanted cells up to 12 months
post-trasplantation7 but in most cases follow-up was
limited to 4-12 weeks meaning that the long-term sur-
vival of implanted cells is still unclear. On the other
hand, the percentage of cells capable of engraftment in
the myocardium, even a few weeks after implantation,
is extremely low, ranging between 1% and 6%.8
Most experimental studies show myoblast trans-
plantation contributes significantly to improved car-
diac function—principally systolic function (ejection
fraction) but in some cases diastolic function too. In
general, improvement is proportional to the number of
engrafted myoblasts9,10 and is maintained over time.
Although some initial studies suggested skeletal
myoblasts were capable of acquiring cardiac muscle-
like properties and even of transdifferentiating and es-
tablishing electromechanical connections,11 current
evidence indicates myoblast transdifferentiation does
not occur and, moreover, that skeletal muscle fibers
cannot mechanically couple with cardiomyocytes or
establish dense unions.12 However, it also seems clear
that skeletal muscle fibers are capable of acquiring
certain characteristics of cardiac muscle cells and ex-
pressing slow and fast contraction muscle fibers which
favor their resistance to muscle fatigue (Figure 1). 
At this point it is worth commenting on a recently
published study by Reinecke et al13 which shows that
in a mouse model, skeletal myoblasts are capable of
fusion with cardiac muscle cells in vivo. If these re-
sults can be reproduced by other groups, they would
justify the use of skeletal myoblasts as a strategy of
cardiac regeneration demonstrating that at least one
possible mechanism would be fusion between implant-
ed cells and cardiomyocytes resident in the heart.
To date, 5 phase I clinical studies with autologous
skeletal myoblasts in patients with cardiac heart dis-
ease have been published. Results obtained from the
first patient to receive direct intracardiac administra-
tion of myoblasts were published by Menasche et al14
who later described results obtained in a phase I trial
with a total of 10 patients.15 These patients had a his-
tory of myocardial infarction and indication for coro-
nary revascularization surgery. At surgery, they re-
ceived direct intramyocardial injection of skeletal
myoblasts previously obtained from the patients
themselves and cultivated in vitro for 14-16 days.
The results show that revascularization and myoblast
transplantation associated with a significantly im-
proved myocardial function (improved systolic vo-
lume and increased ventricular ejection fraction) to-
gether with signs of increased myocardial viability
shown in positron emission tomography (PET) (Fi-
gure 2). The most important secondary effect found
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was high incidence of ventricular arrhythmias which
in 4 patients required implantation of a ventricular
defibrillator. Whether in the form of summaries
(Dib’s phase I studies with scaled doses of myoblasts
and Siminiak’s group16), or articles,8,17,18 results of 6
studies of cardiac regeneration with skeletal my-
oblasts have been published. These involved 3 dif-
ferent clinical situations: intramyocardial delivery
associated with aortocoronary revascularization
surgery15-17; percutaneous transendocardial delivery18;
or delivery during implantation of a ventricular assis-
tance system.18
What can we deduce from the results of these stu-
dies? In fact, they confirm some of the findings
described in experimental models. Firstly, they show
the feasibility of the procedure. At least 2 studies show
that skeletal myoblasts are anatomically capable of en-
graftment in the heart.8,19 On the other hand, a constant
factor in all of them is the production of functional im-
provement with an increase in ventricular ejection
fraction. However, in most of the studies cell treat-
ment is associated with revascularization surgery mak-
ing it currently impossible to determine whether my-
oblast transplantation alone contributes directly to
functional improvement. It is worth mentioning that
recent research indicates that at best revascularization
surgery makes a very limited contribution to improv-
ing ventricular function. Consequently, this would
support the idea that myoblast transplantation is effi-
cient even though the mechanism that induces the im-
provement is still unknown.20 In any case, only by car-
rying out randomized studies with and without
myoblast delivery together with revascularization
surgery will we be able to determine definitively the
efficacy of this strategy. At the time of writing, at least
3 randomized studies are under way in France, Spain,
and the US. Percutaneous delivery will also enable us
to determine the efficacy of myoblast treatment, as
suggested by the only study published to date.18
One of the most controversial aspects of the use of
myoblasts, which was not, in fact, anticipated by the
experimental studies, has been the appearance of car-
diac arrhythmias.8,15 Although different hypotheses
exist, the mechanism producing these arrhythmias is
unknown and the presence of arrhythmias has not been
constant in all studies.17 Although it is relevant, we
cannot currently confirm that myoblast transplantation
induces cardiac arrhythmias. The results of new clini-
cal and experimental trials should determine whether
myoblasts are arrhythmogenic and establish the possi-
ble mechanism.
One fundamental question is: what is the mecha-
nism through which myoblasts can contribute to im-
proved cardiac function? Several hypotheses exist but
none of them is certain. Skeletal myoblasts may facili-
tate cardiac muscle elasticity, limiting the extent of in-
farction and impeding ventricular remodeling. This
would be an exclusively mechanical effect depending
on the formation of a structure that would support the
muscle, but with a purely passive role. A second
mechanism might depend on the liberation of different
substances and growth factors by myoblasts. These
substances would permit the reorganization of the ex-
tracellular matrix (secretion of metalloprotease),21 in-
duction of angiogenesis (endothelial vascular growth
factor) and even mobilization and nesting of stem cells
derived from other tissues.22 Although much evidence
exists against the integration of myoblasts with car-
diomyocytes, recent studies that show fusion between
myoblasts and cardiomyocytes would support the ar-
gument that myoblasts might act because they would
directly benefit systolic function by incorporating into
cardiac muscle. In our opinion, briefly, this hypothesis
appears somewhat unlikely. Various mechanisms may
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Fig. 1. Human myoblast culture.
Upper panel: flow cytometric
identification of skeletal myo-
blasts by expression of CD56
antigen and non-expression 
of CD45 antigen. Skeletal myo-
blasts are positive for desmin.
Lower panel: immunofluorescen-
ce analysis shows myoblasts ex-
press transcript factors associa-
ted with muscular differentiation
(Myo-D) and desmin.
contribute to its efficacy and in acute or chronic situa-
tions the mechanisms may differ. In acute infarction,
action on ventricular modeling might be more effi-
cient; in chronic infarction a passive mechanical
mechanism might offer advantages. Independently of
the nature of the mechanism, there can be no doubt
that animal studies together with the preliminary clini-
cal evidence justify continuing clinical trials that will
permit us to determine the therapeutic efficacy of this
treatment.
Bone Marrow-Derived Stem Cells
In this case the panorama is more complicated. Dif-
ferent populations of bone marrow-derived stem cells
are capable, at least in vitro, of differentiating into car-
diac muscle or endothelial cells and contributing to
contractile function, and to angiogenesis and vasculo-
genesis. Bone marrow is a complex microenviron-
ment. In contrast to what has happened in the case of
skeletal myoblasts, where studies in patients have be-
gun after several years of experimentation, the clinical
application of bone marrow has begun with less pre-
clinical evidence of efficacy. This does not mean there
is no rational basis for their use but, simply, that their
efficacy in animal models has been documented to a
lesser extent. 
We can divide the studies of cardiac regeneration
with bone marrow-derived cells into those with non-
selected populations and those with purified stem cells
(endothelial or hematopoietic) and those that use me-
senchymal cells.
To date, most clinical studies with bone marrow-
derived stem cells have used non-selected cells: that
is, a cell pool that includes stem cells and differentiat-
ed cells. Justification for this is easily understood: the
procedure is simple (to carry out a selection of cells
using a density gradient is within the scope of any la-
boratory), cheap and not subject to the regulatory pro-
cedures required for in vitro cell manipulation. Theo-
retically, by using all the bone marrow cell population
we avoid losing cells that are potentially useful,
whether for their capacity to differentiate into car-
diomyocytes or endothelial cells or liberate substances
that favor cellular regeneration. On the contrary, we
introduce cell types capable of inducing adverse
effects by liberating inflammatory substances. In gene-
ral, experimental studies with mononuclear bone
marrow-derived cells offer contradictory results. Some
research indicates an improvement in vascularization
and cardiac function,23,24 whereas other studies show
no benefit at all.25,26 The heterogeneity of the implan-
ted cells makes it difficult to compare these studies.
Clinically, mononuclear bone marrow- or peripheral
blood-derived cells have been delivered by intracoro-
nary injection in patients with acute myocardial infarc-
tion undergoing angioplasty27-29 or with electro-
mechanical guidance in patients with chronic
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Fig. 2. F-18-fluorodeoxyglucose
(FDG) positron emission tomo-
graphy (PET) imaging. The left-
hand panel corresponds to the
PET image in a post-myocardial
infarction patient. The arrow-
heads point to a deficit of FDG
uptake that would indicate an
image of necrosis. At 3 months
after revascularization surgery
and autologous myoblasts im-
plantation, a highly significant
improvement in FDG uptake can
be seen which would indicate
greater viability. The right-hand
panel corresponds to a patient
who underwent revascularization
surgery without cell transplanta-
tion and in whom improved tis-
sue viability cannot be seen.
ischemia.30-32 These studies aimed to demonstrate the
feasibility of the treatment and its possible efficacy in
terms of improved cardiac function, perfusion and tis-
sue viability. In some of the studies, results of cell
treatment have been compared with control groups re-
ceiving similar treatment but without cell transplanta-
tion. However, these were not randomized clinical tri-
als27,30 and on the whole, results suggest the treatment
is accompanied by improved cardiac function and in-
creased myocardial perfusion. The most widely
accepted hypothesis is that mononuclear cells increase
vascularization and tissue angiogenesis although this
has certainly not been demonstrated in experimental
models or in humans. In a recent comparative study,
patients with acute infarction and stent implantation
were subsequently randomized in 3 groups: patients
who received mononuclear peripheral blood cells mo-
bilized with granulocyte colony stimulating factor (G-
CSF); patients who received G-CSF; and controls. The
high incidence of restenosis in the patients with G-
CSF has brought the trial to a halt and raised the issue
of the possible secondary effects associated with this
type of treatment as well as adding a certain degree of
skepticism to cell therapy.28
A second option consists of using stem cell popula-
tions with a potential demonstrated at least in in vitro
models. The phenotype of bone marrow-derived
hematopoietic stem cells in the rat is perfectly defined
and the different stem cell populations have been char-
acterized in detail. However, for obvious reasons, re-
constitution studies in humans have not been carried
out so bone marrow-derived stem cell populations are
not as well defined. However, markers, such as the ex-
pression of CD34 and AC133 antigens, are associated
with hematopoietic and endothelial stem cells.
The use of hematopoietic stem cells is founded on
the existence of studies in animal models, principally
rats and mice, which show the capacity of different
stem cell populations to differentiate into endothelial
cells and even cardiomyocytes, contributing to im-
proved cardiac function. We think that because recent
studies directly and explicitly question these initial ex-
periments, it is worth dedicating a few lines to deba-
ting them prior to describing the clinical situation.
The first studies of cardiac regeneration with
hematopoietic stem cells used side population cells in
a model of ischemia in the mouse33 or intravenously
delivered CD34 cells in a model of infarction.34 Both
studies demonstrated hematopoietic stem cells were
capable of contributing to myocardial regeneration
through their capacity for favoring angiogenesis and
vasculogenesis and, possibly, differentiating into car-
diomyocytes. However, the most spectacular results
were reported by Orlic et al35 who, using a model of
acute infarction in mice and administering Lin-c-kit+
hematopoietic stem cells (purified population of
hematopoietic stem cells), demonstrated these cells
were capable of differentiating in vivo into cardio-
myocytes and endothelial cells, contributing to im-
proved myocardial contractility and the survival of the
animals. Controversy has arisen out of 2 recently pu-
blished reports in Nature that not only question the
fact that hematopoietic stem cells differentiate into
cardiomyocytes, but directly doubt Orlic et al and in-
directly question all evidence of transdifferentia-
tion.36,37 While it is true that Orlic et al stimulated the
clinical development of cell therapy with stem cells in
patients with infarction, it would be unjustified to pre-
tend that the entire scientific base that supports clinical
trials in patients with myocardial infarction is to be
found in this one study alone. This is not the place for
a detailed discussion of these 3 contradictory studies,
but we at least want to recall certain specific aspects of
the 2 more recent articles. These studies report nega-
tive results and, as in all studies with negative find-
ings, we cannot ignore the fact that simply, the model
used might not have been adequate. On the other hand,
the only conclusion we can reach about these trials is
that a determined population of hematopoietic stem
cells in mice in a model of acute infarction does not
differentiate into cardiomyocytes (except by fusion);
we cannot enter into therapeutic inefficiency since one
of the studies does not even evaluate it,36 and in the
other the results suggest slightly improved function in
the animals treated with the cells.37 Finally, these stud-
ies only looked at the capacity of a very specific stem
cell population, hematopoietic stem cells, and as other
types of stem cells are found in bone marrow, it cannot
be concluded that bone marrow-derived stem cells are
incapable of myocardial regeneration. In the discus-
sions and conclusions of both articles, the authors
question the carrying out of clinical trials. We consider
this unjustified and suggest that carefully designed,
controlled clinical trials with specific, relevant re-
search questions should be carried out.
A new study, published in 2004, adds a different
perspective: using again hematopoietic stem cells and
a model of infarction in the mouse it is possible to ob-
tain cardiomyocytes from hematopoietic stem cells but
the mechanism is through cellular fusion.38 These fin-
dings concur with an earlier study.39
Intracoronary delivery of endothelial stem cells
(also known as endothelial progenitor cells [EPC]) has
been used in patients with acute myocardial infarction
on the hypothesis that these cells would contribute to
improving angiogenesis and recovering hibernating
tissue.40 The efficacy of bone marrow-derived EPC
was compared with peripheral blood-derived cells and
a control group. Functional results and PET perfusion
study data suggest the efficacy of endothelial stem
cells. Among bone marrow-derived stem cells, the
population of AC133-positive cells is considered par-
ticularly enriched in hemangioblast progenitors, capa-
ble of differentiating into endothelial and hematopoie-
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tic cells. The potential of these cells, and the fact that
it is technically possible to purify them from human
bone marrow or peripheral blood has favored their
clinical use, described for the first time in a group of
post-infarction patients undergoing coronary revascu-
larization surgery.41 Initial results show that a single
dose of 10×106 AC133 cells produced an improvement
in function and myocardial perfusion. Consequently,
the authors have begun a randomized study in which
patients where assigned to receive treatment with
AC133 cells and surgical revascularization or surgery
alone. Preliminary results with the first 20 patients in-
dicate greater functional recovery in the group treated
with AC133 cells (personal communication).
Although mesenchymal stem cells have only been
used as a strategy of cardiac regeneration in animal
models, the cell type is particularly attractive due to its
capacity for in vitro differentiation into cardiac muscle
cells and because a substantial number of cells can be
obtained simply, efficiently and relatively cheaply.
Mesenchymal cells can be obtained from various tis-
sues, principally bone marrow and adipose tissue (also
known as vascular fraction of the stroma). Both adi-
pose tissue- and bone marrow-derived mesenchymal
cells have shown their capacity to differentiate simul-
taneously in vitro into cardiac muscle cells and en-
dothelial cells, making them especially interesting be-
cause they can regenerate the myocardium and
contribute to neoangiogenesis and vasculogenesis.42-44
Bone marrow-derived mesenchymal cells have been
used in experimental models of myocardial infarction
in rats and pigs and have shown their capacity to im-
prove cardiac function45 and differentiate into cardiac
muscle cells.46 Mesenchymal cells, genetically modi-
fied with a survival factor, have produced substantial
improvements in cell survival after implantation in in-
farcted mice.47 However, no published clinical studies
report the use of mesenchymal cells in patients with
myocardial infarction.
CONCLUSIONS
The fundamental issue of the current controversy is
whether adult stem cells (hematopoietic or of another
type) are capable of transdifferentiation or whether ob-
servations that suggest that this occurs can be ex-
plained through other mechanisms, such as cellular fu-
sion, or inclusive this is related to simply incorrect
interpretations of experimental results. The detailed
discussion of this topic is beyond the objectives of the
present article but those readers who are interested are
recommended to read recent review articles.48,49 Nev-
ertheless, we believe it is important to try to transmit a
series of ideas that we hope can help readers reach
their own conclusions in an area of medicine that is
highly emotional and thus be able to interpret many of
the published studies more critically:
1. Bone marrow-derived stem cells are not exclu-
sively hematopoietic stem cells. Consequently, gene-
ralizations lead to confusion. For example, hemato-
poietic stem cells may not differentiate into cardiac
muscle, but bone marrow-derived AC133 or CD34
cells are undoubtedly not exclusively hematopoietic
stem cells as they also include endothelial and even
mesenchymal stem cells. In consequence, their capaci-
ty for differentiating may be much greater than that of
hematopoietic cells.
2. It is not absolutely fundamental that transdiffe-
rentiation and functional integration of stem cells into
tissue should occur for them to be efficient. Doubtless,
this would be ideal, but the fact that it may not occur
does not exclude the possibility that their use may
contribute to therapeutic benefit.
3. Cellular fusion between stem cells and cells resi-
dent in the tissue occurs both in vitro and in vivo.
However, cellular fusion may be a part of cellular re-
pair, as in skeletal muscle where damaged tissue recu-
perates through the proliferation of satellite cells and
their later fusion on transforming into myofibers. In
the specific case of the heart, it is worth remembering
that cardiac muscle is formed by connected and, there-
fore, “fusioned” cells.
4. At least in vitro, it has been clearly demonstrated
that it is possible to reprogram cells and induce trans-
differentiation. Whether these exist in vivo and the ex-
tent to which they may exist, have yet to be proven.
5. If knowing the mechanisms by which a specific
treatment is efficient prior to applying it is the objec-
tive of medicine, we invite our readers to ask them-
selves for how many treatments currently accepted as
efficacious and in daily use, they know all of the
mechanisms by which they function and all the possi-
ble secondary effects, and even then continue to use
them. It would be ideal if we could follow the criteria
proposed by Chien4 prior to initiating the clinical ap-
plication of stem cells, but it would not be realistic or
ethical to impede many thousand of patients from be-
nefiting in order to satisfy scientific knowledge (a
multitude of examples can be found in the history of
medicine). This does not waive our responsibility to
carry out strict, objective research that might enable us
to clarify the possible mechanisms by which this type
of treatment may function50.
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